Uncommon Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2022 Jan 20

PMID 35049698

Authors

Ilaria Attili

Antonio Passaro

Pasquale Pisapia

Umberto Malapelle

Filippo de Marinis

Affiliations

Soon will be listed here.

Abstract

Compound epidermal growth factor receptor () mutations represent a heterogeneous subgroup of non-small cell lung cancer (NSCLC) patients with uncommon mutations. We conducted a systematic review to investigate the available data on this patients' subgroup. Overall, we found a high heterogeneity in the incidence of compound mutations (4-26% of total mutant cases), which is dependent on the different testing methods adopted and the specific mutations considered. In addition, the relative incidence of distinct compound subclasses identified is reported with extreme variability in different studies. Preclinical and clinical data, excluding exon 20 p.T790M compound mutations, show good responses with EGFR tyrosine kinase inhibitors (TKIs) (combined common mutations: response rate (RR) ≥ 75% with either first- or second-generation TKIs; combined common plus uncommon: RR 40-80% and 100% with first-generation TKIs and afatinib, respectively; combined uncommon: RR 20-70%, ~80% and ~75% with first-generation TKIs, afatinib and osimertinib, respectively). Overall, data are consistent in supporting the use of EGFR TKIs in treating compound mutations, taking into account different sensitivity profile of accompanying mutations for selecting the most adequate EGFR TKI for individual patients.

Citing Articles

Hsa_circ_0006006 is a potential biomarker for prognosis and cisplatin resistance in non-small cell lung cancer.

Ding M, Zhao J, Li X Hereditas. 2025; 162(1):32.

PMID: 40055838 PMC: 11889802. DOI: 10.1186/s41065-025-00392-w.

USP22 promotes gefitinib resistance and inhibits ferroptosis in non-small cell lung cancer by deubiquitination of MDM2.

Lu P, Li Z, Xu H Thorac Cancer. 2024; 15(31):2260-2271.

PMID: 39315600 PMC: 11543274. DOI: 10.1111/1759-7714.15439.

Co-Occurring Driver Genomic Alterations in Advanced Non-Small-Cell Lung Cancer (NSCLC): A Retrospective Analysis.

Attili I, Asnaghi R, Vacirca D, Adorisio R, Rappa A, Ranghiero A J Clin Med. 2024; 13(15).

PMID: 39124743 PMC: 11313524. DOI: 10.3390/jcm13154476.

Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO).

Pizzutilo E, Agostara A, Oresti S, Signorelli D, Stabile S, Lauricella C ESMO Open. 2024; 9(6):103592.

PMID: 38878323 PMC: 11233869. DOI: 10.1016/j.esmoop.2024.103592.

Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in exon 18.

Zhang Y, Zeng H, Qi C, Tan S, Huang Q, Pu X Transl Lung Cancer Res. 2024; 13(4):875-884.

PMID: 38736500 PMC: 11082699. DOI: 10.21037/tlcr-24-113.

References

Yang J, Schuler M, Popat S, Miura S, Heeke S, Park K . Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. J Thorac Oncol. 2020; 15(5):803-815. DOI: 10.1016/j.jtho.2019.12.126. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Zhou Y, Ge F, Du Y, Li Q, Cai J, Liu X . Unique Profile of Driver Gene Mutations in Patients With Non-Small-Cell Lung Cancer in Qujing City, Yunnan Province, Southwest China. Front Oncol. 2021; 11:644895. PMC: 8076749. DOI: 10.3389/fonc.2021.644895. View

Passaro A, Mok T, Peters S, Popat S, Ahn M, de Marinis F . Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. J Thorac Oncol. 2020; 16(5):764-773. DOI: 10.1016/j.jtho.2020.12.002. View

Peng L, Song Z, Jiao S . Comparison of uncommon EGFR exon 21 L858R compound mutations with single mutation. Onco Targets Ther. 2015; 8:905-10. PMC: 4410901. DOI: 10.2147/OTT.S78984. View

Kimura S, Tanaka K, Harada T, Liu R, Shibahara D, Kawano Y . Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay. Cancer Sci. 2018; 109(11):3657-3661. PMC: 6215868. DOI: 10.1111/cas.13787. View

Zhang B, Wang S, Qian J, Yang W, Qian F, Lu J . Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas. Cancer. 2018; 124(11):2399-2406. DOI: 10.1002/cncr.31329. View

Jing C, Mao X, Wang Z, Sun K, Ma R, Wu J . Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer. Mol Med Rep. 2018; 18(2):2191-2197. PMC: 6072231. DOI: 10.3892/mmr.2018.9210. View

Bar J, Peled N, Schokrpur S, Wolner M, Rotem O, Girard N . UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN). J Thorac Oncol. 2022; 18(2):169-180. DOI: 10.1016/j.jtho.2022.10.004. View

10.

Li H, Wang C, Wang Z, Hu Y, Zhang G, Zhang M . Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy. Lung Cancer. 2019; 130:42-49. DOI: 10.1016/j.lungcan.2019.02.001. View

11.

Akula S, Kamasani S, Sivan S, Manga V, Vudem D, Kancha R . Computational Analysis of Epidermal Growth Factor Receptor Mutations Predicts Differential Drug Sensitivity Profiles toward Kinase Inhibitors. J Thorac Oncol. 2018; 13(5):721-726. DOI: 10.1016/j.jtho.2018.01.003. View

12.

Syahruddin E, Wulandari L, Sri Muktiati N, Rima A, Soeroso N, Ermayanti S . Uncommon mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients. Lung Cancer (Auckl). 2018; 9:25-34. PMC: 5870662. DOI: 10.2147/LCTT.S154116. View

13.

Lei L, Wang W, Zhu Y, Li J, Fang Y, Wang H . Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multi-center study. Cancer Med. 2019; 9(1):12-18. PMC: 6943154. DOI: 10.1002/cam4.2652. View

14.

Mao L, Zhao W, Li X, Zhang S, Zhou C, Zhou D . Mutation Spectrum of From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory. Pathol Oncol Res. 2021; 27:602726. PMC: 8262202. DOI: 10.3389/pore.2021.602726. View

15.

Kohsaka S, Nagano M, Ueno T, Suehara Y, Hayashi T, Shimada N . A method of high-throughput functional evaluation of gene variants of unknown significance in cancer. Sci Transl Med. 2017; 9(416). DOI: 10.1126/scitranslmed.aan6566. View

16.

Shi Yeen T, Pathmanathan R, Shiran M, Ahmad Zaid F, Cheah Y . Detection of epidermal growth factor receptor mutations in formalin fixed paraffin embedded biopsies in Malaysian non-small cell lung cancer patients. J Biomed Sci. 2013; 20:22. PMC: 3651354. DOI: 10.1186/1423-0127-20-22. View

17.

Tu H, Ke E, Yang J, Sun Y, Yan H, Zheng M . A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. Lung Cancer. 2017; 114:96-102. DOI: 10.1016/j.lungcan.2017.11.005. View

18.

Bazhenova L, Minchom A, Viteri S, Bauml J, Ou S, Gadgeel S . Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Lung Cancer. 2021; 162:154-161. DOI: 10.1016/j.lungcan.2021.10.020. View

19.

Moran T, Taus A, Arriola E, Aguado C, Domine M, Gomez Rueda A . Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study. Clin Lung Cancer. 2020; 21(5):428-436.e2. DOI: 10.1016/j.cllc.2020.04.011. View

20.

Hayashi T, Kohsaka S, Takamochi K, Hara K, Kishikawa S, Sano K . Clinicopathological characteristics of lung adenocarcinoma with compound EGFR mutations. Hum Pathol. 2020; 103:42-51. DOI: 10.1016/j.humpath.2020.07.007. View